Scott M. Coiante
2021
In 2021, Scott M. Coiante earned a total compensation of $1.7M as Chief Financial Officer at Aprea Therapeutics, a 6% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $155,000 |
|---|---|
| Option Awards | $627,770 |
| Salary | $381,100 |
| Stock Awards | $579,000 |
| Total | $1,742,870 |
Coiante received $627.8K in option awards, accounting for 36% of the total pay in 2021.
Coiante also received $155K in non-equity incentive plan, $381.1K in salary and $579K in stock awards.
Rankings
In 2021, Scott M. Coiante's compensation ranked 6,607th out of 12,415 executives tracked by ExecPay. In other words, Coiante earned more than 46.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,607 out of 12,415 | 47th |
Division Manufacturing | 2,852 out of 5,508 | 48th |
Major group Chemicals And Allied Products | 1,255 out of 2,378 | 47th |
Industry group Drugs | 1,119 out of 2,099 | 47th |
Industry Pharmaceutical Preparations | 812 out of 1,549 | 48th |
Source: SEC filing on June 10, 2022.
Coiante's colleagues
We found three more compensation records of executives who worked with Scott M. Coiante at Aprea Therapeutics in 2021.
News
Aprea Therapeutics CFO John Hamill's 2023 pay jumps 62% to $908K
April 25, 2024
Aprea Therapeutics CEO Christian Schade's 2022 pay falls 58% to $1.4M
July 11, 2023
Aprea Therapeutics CEO Christian Schade's 2021 pay slips 17% to $3.2M
June 10, 2022
Aprea Therapeutics CEO Christian Schade's 2020 pay rises 6% to $3.9M
April 28, 2021
Aprea Therapeutics CEO Christian Schade's 2019 pay jumps 520% to $3.7M
April 29, 2020